Wegovy

News

Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.

News

Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.

News

The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.

Digital

GLP-1 receptor agonists like Ozempic and Wegovy are dramatically changing how healthcare professionals approach the treatment of obesity in patients.

News

Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.

News

Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.